迈得医疗工业设备股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 现金管理金额：不超过人民币 30,000.00 万元（含本数），在上述额度范 围内，资金可以滚动使用； 证券代码：688310 证券简称：迈得医疗 公告编号：2025-014 ● 现金管理产品类型：安全性高、流动性好、具有合法经营资格的金融机构 销售的投资产品； ● 现金管理期限：自公司董事会审议通过之日起 12 个月内； ● 履行的审议程序：2025 年 4 月 28 日公司召开第四届董事会第二十六次会 议和第四届监事会第二十三次会议分别审议通过了《关于使用部分闲置自有资金 进行现金管理的议案》。 一、公司拟使用部分闲置自有资金进行现金管理的情况 （一）现金管理目的 在保证公司正常经营所需流动资金的情况下，提高资金利用效率，合理利用 闲置资金，增加公司收益。 （二）资金来源 公司用于现金管理的资金均为公司暂时闲置的部分自有资金。 （三）投资额度及期限 公司委托理财产品单日最高余额不 ...

独立董事候选人声明与承诺 (五) 中共中央组织部《关于进一步规范党政领导干部在企业兼职（任职) 问题的意见》的相关规定（如适用); （六）中共中央纪委、教育部、监察部《关于加强高等学校反腐倡廉建设的 意见》的相关规定（如适用 ); (七) 中国人民银行《股份制商业银行独立董事和外部监事制度指引》等的 相关规定(如适用): （八）中国证监会《证券基金经营机构董事、监事、高级管理人员及从业人 员监督管理办法》等的相关规定（如适用); 本人张颖辉,已充分了解并同意由提名人迈得医疗工业设备股份有限公司董 事会提名为迈得医疗工业设备股份有限公司第五届董事会独立董事候选人。本人 公开声明,本人具备独立董事任职资格,保证不存在任何影响本人担任迈得医疗 工业设备股份有限公司独立董事独立性的关系，具体声明并承诺如下； 一、本人具备上市公司运作的基本知识,熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有五年以上法律、经济会计、财务、管理等履行独立董 事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求: (一)《中华人民共和国公司法》等关于董事任职资格的规定； (二)《中华人民共和 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2025-015 迈得医疗工业设备股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●拟聘任的会计师事务所名称：天健会计师事务所（特殊普通合伙） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | --- | --- | --- | | 成立日期 | 2011年7月18日 | 组织形式 特殊普通合伙 | | 注册地址 | | 浙江省杭州市西湖区灵隐街道西溪路128号 | | 首席合伙人 | 钟建国 | 上年末合伙人数量 人 241 | | 上年末执业人员数 | 注册会计师 | 2,356 人 | | 量 | | 签署过证券服务业务审计报告的注册会计师 904人 | | 2023年（经审计） | 业务收入总额 | 34.83 亿元 | | 业务收入 | 审计业务收入 | 亿元 30.99 | | | 证券业务收入 | 亿元 18.40 | ...

一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行政法规、 规章及其他规范性文件，具有五年以上法律、经济、会计、财务、管理等履行独 立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求; (一)《中华人民共和国公司法》等关于董事任职资格的规定; (二)《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用); (三)中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 ( 离 ) 休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定〈如 适用): 独立董事提名人声明与承诺 提名人迈得医疗工业设备股份有限公司董事会,现提名何涛为迈得医疗工业 设备股份有限公司第五届董事会独立董事候选人，并已充分了解被提名人职业、 学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等情况。被 提名人已书面同意出任迈得医疗工业设备股份有限公司第五届董事会独立董事 候选人（参见 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2025-019 迈得医疗工业设备股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 5 月 20 日 13 点 30 分 召开地点：浙江省玉环市沙门镇滨港工业城迈得医疗工业设备股份有限公司 会议室 （五） 网络投票的系统、起止日期和投票时间。 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 20 日 至2025 年 5 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 迈得医疗工业设备股份有限公司（以下简称"公司"） 第四届监事会第二十 三次会议（以下简称"本次会议"）于 2025 年 4 月 28 日以现场方式在公司会议室 召开。本次会议的通知已于 2025 年 4 月 18 日以电子邮件方式送达全体监事。本 次会议由监事会主席王兆平先生召集并主持，应出席会议监事 3 人，实际出席会 议监事 3 人。本次会议的召集、召开符合《中华人民共和国公司法》等法律、 行政法规以及《迈得医疗工业设备股份有限公司章程》的相关规定。 证券代码：688310 证券简称：迈得医疗 公告编号：2025-012 迈得医疗工业设备股份有限公司 第四届监事会第二十三次会议决议公告 二、监事会会议审议情况 经与会监事审议表决，通过了如下议案： (一)审议通过了《关于公司2024年度监事会工作报告的议案》 经审议，监事会同意《公司 2024 年度监事会工作报告》。 表决结果：同意：3 票；反对：0 票；弃权：0 票。 本议案尚需提交公司股东大会审 ...

迈得医疗工业设备股份有限公司 第四届董事会第二十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688310 证券简称：迈得医疗 公告编号：2025-011 一、董事会会议召开情况 迈得医疗工业设备股份有限公司（以下简称"公司"）第四届董事会第二十六 次会议（以下简称"本次会议"）于 2025 年 4 月 28 日以现场加通讯的方式在公司 会议室召开。本次会议的通知已于 2025 年 4 月 18 日以电子邮件方式送达全体董 事。本次会议由董事长林军华先生召集并主持，应出席会议董事 7 人，实际出席 会议董事 7 人。本次会议的召集、召开符合《中华人民共和国公司法》等法律、 行政法规以及《迈得医疗工业设备股份有限公司章程》的相关规定。 二、董事会会议审议情况 经与会董事审议表决，通过了如下议案： (一)审议通过了《关于公司 2024 年度总经理工作报告的议案》 经审议，董事会同意《公司 2024 年度总经理工作报告》。 表决结果：同意：7 票；反对：0 票；弃权：0 票。 (二)审议通过了《关于 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2025-016 迈得医疗工业设备股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 迈得医疗工业设备股份有限公司（以下简称"公司"）2024年度利润分配 预案为：不派发现金红利，不送红股，不以资本公积金转增股本。 公司2024年度利润分配预案已经公司第四届董事会第二十六次会议、第 四届监事会第二十三次会议审议通过，尚需提交公司2024年年度股东大会审议。 充分考虑到公司的经营情况和发展规划，为更好维护全体股东长远利益，保 障公司可持续发展，经公司董事会决议，公司拟定 2024 年度利润分配方案：不 派发现金红利，不送红股，不以资本公积转增股本。 本次利润分配方案尚需提交公司 2024 年年度股东大会审议。 二、2024 年度不进行利润分配的情况说明 鉴于公司 2024 年度归属于上市公司股东的净利润为负，未实现盈利，同时 公司正处于业务线拓展的重要阶段，当前以及未来发展需保持充足的资金；结合 公司实际经 ...

Financial Performance - The company reported a profit distribution plan for 2024, which includes no cash dividends, no bonus shares, and no capital reserve conversion into shares [8]. - The company has not achieved profitability since its listing, indicating ongoing investment in growth and development [6]. - In 2024, the company's operating revenue was CNY 274,850,777.34, a decrease of 42.77% compared to CNY 480,220,256.00 in 2023 [24]. - The net profit attributable to shareholders was a loss of CNY 19,981,182.92 in 2024, down 120.02% from a profit of CNY 99,828,173.71 in 2023 [24]. - The net cash flow from operating activities decreased by 49.00% to CNY 56,563,516.68 in 2024, compared to CNY 110,908,655.20 in 2023 [27]. - The company's total assets at the end of 2024 were CNY 1,053,411,101.81, down 8.39% from CNY 1,149,858,761.63 at the end of 2023 [24]. - The company reported a decrease in net assets attributable to shareholders by 9.37% to CNY 810,050,019.65 at the end of 2024 [24]. - The company faced increased competition and reduced customer investment willingness, impacting revenue negatively [26]. - The company’s revenue decreased due to fluctuations in downstream market demand and increased competition, leading to a decline in operating income [141]. Research and Development - Research and development expenses accounted for 14.70% of operating revenue in 2024, an increase of 7.79 percentage points from 6.91% in 2023 [25]. - The total R&D investment for the year reached ¥40,411,899.21, an increase of 21.81% compared to the previous year [111]. - The company submitted 146 new patent applications during the reporting period, including 21 invention patent applications [39]. - The company has received multiple accolades for its products, including recognition as the first domestic product in various categories from 2017 to 2024, highlighting its innovation and industry leadership [70]. - The company has established a comprehensive R&D system across eight major modules, enhancing its innovation and talent development efforts [124]. - The company has developed numerous core technologies in automated production, including high-speed multi-channel feeding technology and medical soft catheter shaping technology, which are leading in the domestic market [123]. - The company is actively engaged in the research and development of GLP-1 drugs to capitalize on the growing market [103]. Operational Risks and Compliance - The company faces potential operational risks, which are detailed in the report, emphasizing the need for investor caution [6]. - The audit report from Tianjian Accounting Firm confirmed a standard unqualified opinion, ensuring the accuracy of the financial statements [7]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties, ensuring financial integrity [10]. - The company has not violated decision-making procedures for external guarantees, maintaining compliance with regulations [10]. - The company has established a comprehensive internal control system and governance mechanism to improve risk management and ensure compliance with legal regulations [40]. Market Trends and Industry Insights - The domestic medical consumables industry is experiencing continuous growth, driven by factors such as an aging population and increasing healthcare expenditures, with a projected steady growth trend [65]. - The intelligent manufacturing equipment industry in China is benefiting from strong government support and the integration of new information technologies, leading to rapid market growth and expansion opportunities [64]. - The demand for intelligent production equipment in the medical consumables sector is increasing due to stricter government regulations and rising labor costs, creating a favorable market environment for intelligent equipment manufacturers [66]. - The medical device market is experiencing a slowdown in growth, with investment amounts declining year-on-year [142]. Strategic Initiatives and Future Plans - The company has outlined its future plans and development strategies, which are subject to investment risks and do not constitute a commitment to investors [9]. - The company plans to invest in the "Annual Production of 35 Units of Medical Equipment Intelligent Equipment Expansion Project" to enhance production efficiency and supply capacity, utilizing part of the raised funds for this initiative [190]. - The company aims to become a global leader in medical consumables automation, focusing on enhancing technology levels and developing intelligent equipment to improve assembly efficiency and product quality for downstream manufacturers [188]. - The company intends to expand its market presence in Europe, the Americas, and developing countries, aiming to increase product market penetration and share [194]. Investor Relations and Governance - The company actively engages in investor relations to enhance communication and improve its image in the capital market [40]. - The company will strengthen investor relations management to protect minority shareholders' rights and ensure compliance with relevant laws and regulations [196]. - The company plans to optimize organizational management to enhance operational efficiency and competitiveness through improved governance structures and decision-making mechanisms [198].

Financial Performance - The company's operating revenue for Q1 2025 was ¥40,176,271.66, a decrease of 45.87% compared to ¥74,220,852.42 in the same period last year[3] - The net profit attributable to shareholders was -¥10,797,370.24, representing a decline of 202.7% from a profit of ¥10,513,161.20 in the previous year[3] - The basic earnings per share were -¥0.07, a decrease of 216.67% from ¥0.06 in the same period last year[3] - The diluted earnings per share also stood at -¥0.07, showing a decline of 216.67% compared to the previous year's ¥0.06[3] - The weighted average return on equity was -1.34%, a decrease of 2.51 percentage points from the previous year's 1.17%[3] - The net loss for Q1 2025 was CNY 13,352,887.54, compared to a net profit of CNY 9,614,159.23 in Q1 2024, indicating a significant decline in profitability[19] - The total equity attributable to shareholders decreased to CNY 784,825,447.22 in Q1 2025 from CNY 810,050,019.65 in Q1 2024, a decline of 3.1%[17] Cash Flow - The net cash flow from operating activities increased by 187.24% to ¥29,713,887.51, up from ¥10,344,617.70 in the same period last year[3] - Cash flow from operating activities for Q1 2025 was $29,713,887.51, a significant increase from $10,344,617.70 in Q1 2024, representing a growth of 187.5%[22] - Total cash inflow from investment activities in Q1 2025 was $146,353,661.00, compared to $5,330,784.87 in Q1 2024, indicating a substantial increase[22] - Net cash outflow from investment activities was -$35,241,358.69 in Q1 2025, worsening from -$23,828,213.47 in Q1 2024[23] - Cash flow from financing activities generated a net inflow of $4,822,770.54 in Q1 2025, compared to an inflow of $890,109.18 in Q1 2024[23] - The company reported a net cash increase of -$627,811.49 in Q1 2025, compared to -$12,378,088.04 in Q1 2024, showing an improvement in cash flow dynamics[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,088,739,539.60, reflecting a 3.35% increase from ¥1,053,411,101.81 at the end of the previous year[4] - Total liabilities rose to CNY 271,484,133.79 in Q1 2025, up from CNY 207,957,231.30 in Q1 2024, marking an increase of 30.6%[17] - The company's total assets increased to CNY 1,088,739,539.60 in Q1 2025 from CNY 1,053,411,101.81 in Q1 2024, representing a growth of 3.4%[17] Research and Development - Research and development expenses totaled ¥9,155,975.84, accounting for 22.79% of operating revenue, an increase of 9.48 percentage points from 13.31%[4] - Research and development expenses for Q1 2025 were CNY 9,155,975.84, slightly down from CNY 9,880,803.80 in Q1 2024, showing a decrease of 7.3%[18] Share Repurchase - As of March 31, 2025, the company has repurchased a total of 2,592,575 shares, accounting for 1.56% of the total share capital of 166,219,690 shares[12] - The total amount spent on share repurchase is RMB 29,156,636.67, with a maximum transaction price of RMB 13.45 per share and a minimum of RMB 9.30 per share[12] - The company plans to use repurchased shares for employee stock ownership plans or equity incentives, with a repurchase budget between RMB 15 million and RMB 30 million[11] Market Conditions - The decline in revenue and net profit was primarily attributed to fluctuations in downstream market demand and reduced customer investment willingness[6] Shareholder Information - The top ten shareholders hold a combined 47.15% of the shares, with Lin Junhua being the largest shareholder at 47.15%[9] - The company has not identified any related party relationships among the top ten shareholders, except for Lin Junhua's connection with Taizhou Saina Investment Consulting Partnership[10] - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[10]